Newly developed retatrutide, a twin -action treatment targeting equally GLP-1 and GIP receptors, is generating considerable interest within the healthcare community. Preliminary clinical studies have shown impressive reductions in physical size and advancements in metabolic markers for people with overweight. Scientists believe this ground-breakin